| Literature DB >> 29623270 |
Samantha M Harden1, Matthew Lee Smith2,3,4, Marcia G Ory2,3, Renae L Smith-Ray5, Paul A Estabrooks6, Russell E Glasgow7.
Abstract
The RE-AIM Framework is a planning and evaluation model that has been used in a variety of settings to address various programmatic, environmental, and policy innovations for improving population health. In addition to the broad application and diverse use of the framework, there are lessons learned and recommendations for the future use of the framework across clinical, community, and corporate settings. The purposes of this article are to: (A) provide a brief overview of the RE-AIM Framework and its pragmatic use for planning and evaluation; (B) offer recommendations to facilitate the application of RE-AIM in clinical, community, and corporate settings; and (C) share perspectives and lessons learned about employing RE-AIM dimensions in the planning, implementation, and evaluation phases within these different settings. In this article, we demonstrate how the RE-AIM concepts and elements within each dimension can be applied by researchers and practitioners in diverse settings, among diverse populations and for diverse health topics.Entities:
Keywords: dissemination and implementation research; evaluation framework; health promotion; implementation science; knowledge transfer; translation
Year: 2018 PMID: 29623270 PMCID: PMC5874302 DOI: 10.3389/fpubh.2018.00071
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Iterative and temporal application of the RE-AIM framework.
Examples of applying RE-AIM dimension(s) in different settings across different phases of projects.
| Project stage | Clinical | Community | Corporate | Overall |
|---|---|---|---|---|
| Consider the project impact on all RE-AIM dimensions and prioritize the focus for planning and evaluation | ||||
| Attempt to keep the target population as large and diverse or representative as possible for a greater public health impact. | ||||
| Determine how each dimension will be included in the project: describe, assess, and/or intervene | ||||
| Avoid the publication bias for solely reporting on the effect of an intervention on the desired outcome/behavior change without describing or assessing other interventions. | ||||
| Develop data collection and reporting procedures and timelines for selected RE-AIM dimensions | Consider the metrics of interest and how data will be transferred. | Pragmatically consider what is feasible to collect based on the intended purpose of the intervention. | Consider the messages important for key stakeholders and the data that will drive such messages. | Consider “balancing metrics” and unintended outcomes; as well as assessing and reducing potential health inequities |
| Engage all project staff and partners in processes to ensure transparency, equity, compliance with regulations, and support (ongoing throughout the project) | ||||
| Consider structure of the clinical health-care organization and potential stakeholders including nurses, nurse assistants, physicians, patients/family, and administrators. | Bring together stakeholders from diverse sectors (e.g., government, academia, faith-based, aging) to allow each to vocalize their “pain points” and definitions for success. | Engaging multiple employee types (leadership, different divisions/roles) in conversations about new initiatives brings a sense of ownership, which can bolster initial and ongoing support. By including multiple employee perspectives in the planning phase, the logistics about implementation and anticipated outcomes will be identified, which will increase initial adoption and the potential for long-term maintenance | Diverse perspectives allow all parties to provide feedback about processes and procedures so that a coordinated approach can be devised and executed with fidelity. | |
| Plan for sustainability and generalizability from the outset | Consider how intervention- and assessment-components can be implemented in settings with different histories, resources, workflows | Develop a coalition or advisory board to be engaged throughout the process, including those not directly involved in the project, to identify information and resources needed to increase the likelihood of sustainability | Include staff with clinical expertise to be engaged throughout the process, including those not directly involved in the project | Design for feasibility, success, and dissemination that addresses each of RE-AIM dimensions. |
| Monitor data periodically and at key points for each dimension (emphasis on priority dimensions) | Have brief (perhaps “automated”), ongoing data collection. Use rapid, pragmatic assessments to identify reasons for initial results | Conduct training for program delivery staff about data collection procedures including data completion and quality checks. Routinely export available data from administrative records and secondary sources to track real-time changes | Have brief “automated” ongoing data collection from routine company records. When supplementary outcome measures are used, conduct training for program delivery staff about data collection procedures including data completion and quality checks. Routinely export available data from administrative records and secondary sources to track real-time changes | Pragmatic, timely, and low-resource data collection for ongoing decision-making and engagement in the PDSA cycle over time and dimensions |
| Track implementation and costs as well as fidelity to core components if those are priority dimensions | Discuss and implement low burden cost assessments (interviews, tracking, observations) at key time points | Develop systems for fidelity monitoring (observation) and adherence to delivery protocol. Programs that breach fidelity are subject to additional unplanned costs (e.g., cost per participant increases if workshops are not filled to capacity) | Track implementation and variability across sites. Routinely compare outcomes across a random sample of sites as a way of identifying unanticipated fluctuations and potential protocol deviations | Real-time issues can be addressed more rapidly. Avoids type 3 error (concluding that intervention did not work when perhaps delivery was not consistent with evidence-based components) |
| Perform ongoing assessments of project evolution and adaptations | Probe adaptations to address each RE-AIM dimension. | Routinely export available data from administrative records and secondary sources to track real-time progress. Regularly debrief with program deliverers and organizational partners to identify (and adapt to address) unforeseen challenges | Track implementation and impact over time and across settings and staff. | Need to capture real-world adaptations to systematically collect data on how, why, when, and by whom changes are being implemented in the field |
| Reconsider the intervention impact on (and priorities for) all RE-AIM dimensions | Use both quantitative and qualitative assessments. In applied cases, use “good enough” methods—ballpark estimates make them work when “gold standard” methods are not feasible | Assess whether the number of participants reached will enable meaningful outcomes to be observed and adjust recruitment/delivery accordingly. Discuss project progress with program deliverers, partnering organizations, and other key stakeholders regularly to ensure transparency and identify changes in priorities for the project | Assess program impact on “bottom line” and estimated return-on-investment. | Continued discussion with stakeholders ensures that the appropriate impact is being achieved. |
| Decide if adaptations are needed to address problems with outcomes on one or more RE-AIM dimensions | Pilot and then implement intervention or implementation strategy adaptations needed to improve performance, and track their impact | Assess the appropriateness of participants engaged in the intervention to determine if appropriate and equitable outcomes are observed. Depending on what is seen, there may be implications for refining participant recruitment and retention procedures | Test different intervention or implementation strategy adaptations needed to improve performance, and track their impact | Prioritize adaptations and test their impact across dimensions (see Figure |
| Evaluate the impact on all relevant RE-AIM dimensions | Consider subgroup as well as overall effects. Consider overall impact on quality of life and patient-centered outcomes. Include balancing measures | Begin with priority dimensions and “low-hanging fruit”. Reach and implementation measures may be easily assessed, whereas adoption and maintenance may require more in-depth processes to identify | Consider subgroup effects in addition to overall outcomes. Based on findings, target intervention to streamline resources and impact | Return to RE-AIM plan and summarize accordingly. |
| Calculate costs and cost-effectiveness for each RE-AIM dimension | Report costs from perspective of multiple stakeholders—adopting settings; clinical team; and patients. Estimate replication costs in different settings or under different conditions | Consider the benefits of cost and cost-effectiveness in terms of expanding the initiative geographically versus scaling-up in your local area (or both). Costs may differ for new initiatives relative to those that are ongoing | Summarize return-on-investment and expected rate of return | Communication and evaluation of costs contributes to generalizability of the intervention |
| Determine why and how observed RE-AIM results occurred | Consider using mixed methods to blend objective data (the “what”) and impressionistic data (the “why and how”) to gain a more comprehensive understanding about the context of intervention successes and challenges | Share findings with stakeholders within and external to organizations to contextualize and interpret findings. Multiple perspectives will drive decisions about impact, needed adaptations, and grand-scale dissemination (if appropriate) | Collect stories and reports about keys to success and share these at meetings, on company websites, etc. | Contribute to the understanding of the mechanisms that achieved the effect for multiple populations, settings and staff |
| Disseminate findings for accountability, future projects, and policy change | Base statistical findings on clinically significant findings valued by clinicians. | In community settings, general findings about improvements seen among participants and testimonials may be appropriate for community residents and partnering organizations | In corporate settings, metrics related to productivity and staff absenteeism may be most appropriate for leadership to assess cost–benefits of employee-level interventions. Staff outcomes and program feedback may be indicative of overall employee engagement | Determine the most appropriate format to distribute findings and which messages are most meaningful for that audience |
| Plan for replication in other settings based on results | Summarize lessons learned and provide guides for implementation and adaptation for different types of settings | Consider reporting venues and organizations to share results (e.g., community-based organizations, governmental agencies) | Consider issues of scalability and how to efficiently implement successful programs company-wide (with appropriate adaptations) | Develop implementation and adaptation guides for future applications and new settings |
*HIPPA, health insurance portability and accountability act; BAA, business associate agreement; DUA, data use agreement.